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Abstract
Background: Parkinson's disease is a progressive neurodegenerative disorder, where most cases are sporadic
with a late onset. In rare incidences familial forms of early-onset parkinsonism occur, and when recessively
inherited, cases are often explained by mutations in either the parkin (PARK2) or PINK1 (PARK6) gene or on
exceptional occasions the DJ-1 (PARK7) or ATP13A2 (PARK9) gene. Recessively inherited deletions/duplications
and point mutations in the parkin gene are the most common cause of early-onset parkinsonism known so far,
but in an increasing number of studies, genetic variations in the serine/threonine kinase domain of the PINK1 gene
are found to explain early-onset parkinsonism.
Methods: In this study all families were from a population with a high incidence of consanguinity. We investigated
11 consanguineous families comprising 17 affected with recessively inherited young-onset parkinsonism for
mutations both in the parkin and PINK1 gene. Exons and flanking regions were sequenced, and segregation
patterns of genetic variation were assessed in members of the respective families. An exon dosage analysis was
performed for all exons in both genes.
Results: In the parkin gene, a three generation family was identified with an exon 4 deletion segregating with
disease. Both affected were homozygous for the deletion that segregated on a haplotype that spanned the gene
in a haplotype segregation analysis that was performed using additional markers. Exon dosage analysis confirmed
the recessive pattern of inheritance with heterozygous deletions segregating in healthy family members. In the
PINK1 gene we identified two novel putative pathogenic substitutions, P416R and S419P, located in a conserved
motif of the serine/threonine kinase domain. Both substitutions segregated with disease in agreement with a
recessive pattern of inheritance within respective families and both were present as homozygous in two affected
each. We also discuss common polymorphisms in the two genes found to be co-segregating within families.
Conclusion:  Our results further extend on the involvement of PINK1  mutations in recessive early-onset
parkinsonism with clinical features similar to carriers of parkin mutations.
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Background
Parkinson's disease (PD) is a neurodegenerative disorder
recognised by a combination of the different motor symp-
toms rigidity, tremor, postural instability and bradyki-
nesia [1,2]. Although the onset of PD is, in most cases,
considered to be sporadic, individuals with a first-degree
relative with PD are at greater risk of developing disease.
According to familial aggregation studies the risk of devel-
oping PD for first-degree relatives is 2–14 times higher
than for those with no family history of PD with relatives
of late-onset at the lower and early-onset at the higher end
of the range [3-5].
Only a few genes are known to be recessively inherited in
early-onset parkinsonism. These genes are parkin  [6],
PINK1 [7], DJ-1 [8] and ATP13A2 [9]. The most common
form of early-onset parkinsonism known so far is auto-
somal recessive juvenile parkinsonism (AR-JP), caused by
loss-of-function mutations in the parkin gene [10]. AR-JP
was first discovered and described in Japanese families
[11-14] and subsequently linked to 6q25.2-27 [PARK2;
OMIM 600116] [15]. The parkin gene was characterized
by Kitada et al. [6], and has four motifs; an ubiquitin-like
domain in the amino-terminal and a RING1-in-between-
RINGS (IBR)-RING2 structure in the carboxyl terminal
[16]. This characteristic structure links the Parkin protein
to the ubiquitin-proteasome system [6].
Different classes of mutations have been described in the
parkin gene [6] and recent studies have identified several
deletions, duplications and point mutations in individu-
als with this form of parkinsonism [17-20] estimated to
be responsible for 50% of autosomal recessive early-onset
and 18–20% of sporadic early-onset cases of parkinson-
ism [10,21]. A possible role for autosomal dominant or
compound heterozygous effects of mutations has also
been suggested [22].
PINK1 was identified as the gene associated to the PARK6
candidate region of PD, mapped to 1p36 [PARK6; OMIM
605909] by Valente and colleagues [7,23,24]. The gene
encodes a PTEN-induced putative kinase1 (PINK1) with a
serine/threonine kinase motif and a mitochondrial target-
ing sequence [7]. Recently, several mutations in PINK1
have been recognised as disease causative in a growing
number of families with early-onset autosomal recessive
parkinsonism [25-30], and in sporadic early-onset parkin-
sonism [31]. The effect of heterozygous mutations and a
possible existence of gain of function mutations with
dominant transmission has been discussed [32].
Most PD associated mutations have been identified in the
serine/threonine kinase domain potentially affecting the
kinase activity or possibly the substrate binding ability
[7,25-27,29,32-38]. The serine/threonine kinase activity
of this segment was confirmed by Sim and colleagues [33]
using the kinase domain and C-terminal in truncation
experiments. Cell culture studies identified a mitochon-
drial localisation and function of PINK1 [39].
Clinically, patients with parkin mutations are observed as
levodopa-responsive parkinsonism [41,42] with a rela-
tively long duration and slow progression [40,41]. As a
generalization, the common symptoms of PINK1 muta-
tion carriers are clinically described as comparative to
symptoms of sporadic PD except for earlier onset and
slower disease progression [28,30,34], however, some-
times without dystonia and sleep benefit, which is com-
mon for carriers of parkin mutations [7,10].
We examined families from Jordan with a high incidence
of consanguineous marriages, a recessive pattern of inher-
itance, and at least one patient with parkinsonism in each
family to investigate the significance of parkin and PINK1
mutations in the region. In light of the ongoing discussion
regarding the impact of heterozygous mutations in both
parkin and PINK1, and to discuss a possible effect of muta-
tional load, we present nearly full distribution of substitu-
tions observed.
Methods
Patients
This study included 11 consanguineous families with 1–2
affected with juvenile or young-onset parkinsonism with
a total of 59 family members with 17 affected. Five fami-
lies had only one affected member strictly classified as
having young-onset sporadic parkinsonism. The age at
onset was on average 26.8 ± 5.8 years [range 19–36] cov-
ering cases defined as either young (≥ 21 and <40) or juve-
nile (<21) onset [43,44].
The parents were unaffected with the absence of disease in
several generations suggesting an autosomal recessive
mode of inheritance. Clinical manifestations included
marked response to levodopa (60%), sleep benefit (95%),
observed L-dopa induced dyskinesia (90%), dystonic pos-
ture (90%), and a slow disease progression (90%). Fami-
lies A, B, C, D, E and K were inhabitants of the same
geographic region in north-Jordan while families F, G, H,
I and J were inhabitants at different locations of mid-Jor-
dan.
Genetic studies
DNA was collected from all available family members.
Blood samples were collected on EDTA tubes after gather-
ing informed consent from each participant in compli-
ance with the Helsinki Declaration and the project was
approved by the research ethics committee for research on
human, headed by the dean of Medical School Jordan.
DNA was extracted using Wizard®  DNA Extraction kitBMC Neurology 2008, 8:47 http://www.biomedcentral.com/1471-2377/8/47
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(Promega). All DNA samples were amplified using
GenomiPhi DNA Amplification Kit (Amersham Bio-
science Corp) due to limited amounts of DNA. Verifica-
tion of family relations were performed with the
AmpFlSTR® profiler® kit (Applied Biosystems, Foster City,
CA, USA) according to the manufacturer's protocol.
Coding regions of parkin (exons 1–12, primers available
on request) and PINK1 (exons 1–8) were sequenced using
primers from Hatano et al [25] and additional primers for
exon 5 from Schlitter et al [45]. DNA amplification was
performed with 10 μM of each primer, GeneAmp 10×
buffer II (Applied Biosystems), 25 μM MgCl2, 10 μM
dNTP and Taq Polymerase (250 Units, 5 U/μl). The PCR
was run for 45 cycles at 96°C for 30 sec, annealing tem-
perature for 30 sec and 72°C for 30 sec. Sequencing reac-
tions were performed with BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems) according to manu-
facturers manual using 3,2 pmol primer and 30–90 ng
DNA template, run for 25 cycles at 96°C for 10 sec,
annealing temperature for 5 sec and 60°C for 4 min. Spe-
cial PCR procedure was used for the GC rich exon 1
(method available on request).
To perform haplotype segregation analysis we genotyped
four microsatellite markers (D6S1599, D6S305, D6S411
and D6S1550) frequently analysed in parkin. The markers
were amplified using 10 μM of each primer, GeneAmp
10× buffer II (Applied Biosystems), 25 μM MgCl2, 10 mM
dNTP and Taq polymerase Gold (250 units, 5 U/μl). The
PCR was run for 40 cycles at 96°C for 30 sec, annealing
temperature for 30 sec and 72°C for 30 sec.
To map the deletion size, PCR reactions were performed
of ~200 bp fragments at increasingly closer intervals to the
breakpoints according to the following conditions; 10 μM
of each primer, GeneAmp 10× buffer II (Applied Biosys-
tems), 25 μM MgCl2, 10 mM dNTP and Taq polymerase
Gold (250 units, 5 U/μl). The PCR was run for 45 cycles at
96°C for 30 sec, annealing temperature for 30 sec and
72°C for 30 sec.
Multiple sequence alignment was performed using Clus-
talW software available at the European Bioinformatics
Institute http://www.ebi.ac.uk/clustalw/ to evaluate con-
servation of amino acids in the parkin and PINK1 gene
across species. Tolerance of the substitutions observed was
predicted using SIFT v.2 http://blocks.fhcrc.org/sift/
SIFT.html. Gene exon dosage analysis was performed
using the SALSA MLPA P051/P052B kit (MRC-Holland)
according to the manufacturer's protocol. Fragments were
analysed using GeneMapper v3.7 (Applied Biosystems)
and interpretation of results was performed with the Cof-
falyser v4 software package (MRC-Holland). When not
specified in method, fragments and sequences were ana-
lysed on an ABI 3130xl Genetic Analyzer (Applied Biosys-
tems, Foster City, CA, USA)
Results
In Family F, a three generational pedigree we identified an
exon 4 deletion in the parkin gene and substitutions in the
PINK1 gene co-segregating with disease making an inter-
esting contribution to the discussion on possible digenic
effects. Additionally, two non-synonymous substitutions
and one synonymous substitution was observed in the
parkin gene (figure 1a,c). Five non-synonymous substitu-
tions and three synonymous substitutions were identified
and among these, two novel substitutions, P416R and
S419P, are proposed to be pathogenic mutations. In six
families there were carriers of one or more of the PINK1
non-synonymous substitutions. In four of these families,
substitutions were present as homozygous or compound
heterozygous in affected individuals where substitutions
segregated with disease in a pattern compatible with reces-
sive inheritance (figure 1b–f) (Overview Table 1).
Non-synonymous substitutions
In the parkin gene, Gln34Arg (202A>G) was observed in
family G (patient II.3) whereas Val380Leu (1139G>C)
was observed in family A (patient II.2). Both were in het-
erozygous state (Segregation patterns figure 1a,c). Multi-
ple sequence alignment showed that Gln34Arg is
conserved across mammals and that Val380Leu is limited
conserved across mammals (Figure 2a). Both substitu-
tions were predicted by SIFT to be tolerated with a high
degree of sequence information (Seq Rep = 0.78).
In the PINK1 gene four non-synonymous substitutions
were in the serine/threonine kinase domain located to
amino acids 156–509 [7]. Substitutions identified in this
domain was in exon 5 (A340T), exon 6 (P416R) and exon
7 (S419P and E476K). An additional non-synonymous
substitution was located in a large conserved domain 3' of
the kinase domain (Figure 2b).
The A340T substitution is in a region conserved in pri-
mates but not throughout mammals, as illustrated in Rat-
tus norwegicus as well as in Mus musculus where threonine
is the conserved amino acid (Figure 2b). This substitution
is found in two families (family F and J, Figure 3b and fig-
ure 1f).
In this material, the substitution in the most conserved
region is the P416R substitution located in an APE site
within the kinase domain, a universally conserved activa-
tion segment motif and most likely essential for protein
function. This mutation was found in a single family
(family G) and was homozygous in both affected individ-
uals (Figure 1c). In close proximity to this universally con-
served APE motif is the S419P substitution. This is aBMC Neurology 2008, 8:47 http://www.biomedcentral.com/1471-2377/8/47
Page 4 of 11
(page number not for citation purposes)
putatively important structural change, in a region con-
served across mammals. The substitution was
homozygous in both affected of one family (family I) and
was present together with D391D and N521T both in
homozygous state (Figure 1e).
The E476K substitution represents a change in amino acid
charge in a residue moderately conserved across mam-
mals. In addition, lysine is the species specific amino acid
in the Rattus norwegicus form of the PINK1 gene, indicat-
ing a less severe alteration. Together with N521T this sub-
stitutions was found to segregate with disease in one large
family (family F) and as heterozygous in members of an
additional family (family E, Figure 1b).
The N521T substitution is in exon 8, outside the serine/
threonine kinase region, in a conserved region comprising
a large sequence at the 3' of the protein. The region is con-
served across all mammals but has an unknown function.
The N521T substitution identified in this region is the
most prevalent in our material and also one of the most
common substitution found in cases and family members
with early onset parkinsonism, as well as in controls in
other studies and is regarded as a polymorphism and not
a disease causing mutation [27,31,46]. This variation is
present as compound heterozygous in both affected of
family F and as compound heterozygous in the only
affected of family J (Figure 1f). In family F, the N521T sub-
stitution is present with E476K and in family J it is present
a-f: Family pedigrees with segregation patterns of substitutions identified in Jordanian families with young-onset parkinsonism Figure 1
a-f: Family pedigrees with segregation patterns of substitutions identified in Jordanian families with young-
onset parkinsonism. c The P416R mutation is present as homozygous in both affected of family G. An asterisk shows parkin 
Q34R segregation. e In family I the S419P mutation is present in homozygous state in both affected together with the putative 
polymorphisms D391D and N521. a-f Substitutions presented in the pedigrees. The A340T, E476K and N521T substitutions 
could be discussed, regarding mutational load and effect on disease development. An accumulation of substitutions are 
observed in some of the pedigrees. (N/A -Not available for DNA analysis).
a)
d) e) f)
*
**
*
b) c)BMC Neurology 2008, 8:47 http://www.biomedcentral.com/1471-2377/8/47
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with A340T. The N521T substitution is also present as
homozygous in both affected of family I. However, in
family I the substitution is present with S419P, also
homozygous and presumably the most prominent substi-
tution of the two. A juvenile onset of parkinsonism was
observed in family H with the affected only heterozygous
for N521T.
We did not identify any non-synonymous substitutions
within family A-D and K which were all from the same
region in Jordan (north-Jordan). Family E was the only
family from that region making an exception with an
E476K non-synonymous substitution in the PINK1 gene.
The family was identified through a single affected, strictly
classifying this as sporadic young-onset parkinsonism.
Synonymous substitutions
Additionally to the substitutions described above, we
observed a synonymous substitution, Val17Val (152C>T),
in parkin in family G. In PINK1 three synonymous substi-
tutions, L63L in exon 1, D391D in exon 6 and L581L in
exon 8 were identified. The L63L substitution was present
in four affected; family B patient II.1, family D patient II.
2 and family K patient II.1 and patient II.2 (data not
shown in figure 1) and has been identified as a polymor-
phism in a series of studies [45]. The D391D synonymous
substitution was present in a homozygous state in family
I, in both affected. However, these affected are
homozygous for two additional non-synonymous substi-
tutions (figure 1e). The L581L substitution was identified
in an unaffected member of family G (member III.1). Pre-
Table 1: Synonymous and non-synonymous substitutions found in the parkin and PINK1 gene in affected with parkinsonism.
Family Affected Substitutions in Gene Gender Age at onset
Parkin PINK1
Family A II.1 ND ND Male 30
II.2 V380L (He) ND Female 28
Family B II.1 ND L63L (He) Female 23
Family C II.1 ND ND Female 20
Family D II.1 ND ND Female 25
II.2 ND L63L (He) Female 20
Family E II.1 ND E476K (He) Male 20
Family F II.2 Exon4 Δ (H) E476K, N521T (CH) Male 32
II.4 Exon4 Δ (H) E476K, N521T (CH) Male 32
Family G II.2 ND P416R (H) Male 23
II.3 V17V, Q34R (CH) P416R (H) Female 25
Family H II.1 ND N521T (He) Male 19
Family I II.1 ND D391D, S419P, N521T (all H) Female 36
II.2 ND D391D, S419P, N521T (all H) Female 35
Family J II.1 ND A340S, N521T (CH) Male 36
Family K II.1 ND L63L Female 25
II.2 ND L63L Male 27
Putative pathogenic mutations are in bold. CH – compound heterozygous; H – Homozygous; He – Heterozygous; Δ – deletion; ND – none 
detected.
Multiple sequence alignment of substitutions in the parkin and PINK1 gene across species using ClustalW version 1.83 Figure 2
Multiple sequence alignment of substitutions in the parkin and PINK1 gene across species using ClustalW ver-
sion 1.83. Substitutions are highlighted where conserved and flanked by neighbouring amino acids.BMC Neurology 2008, 8:47 http://www.biomedcentral.com/1471-2377/8/47
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dictions using SIFT v.2 strengthened the assumption of
the A340S, E476K and N521T substitutions to be tolera-
ble polymorphisms. P416R was predicted not tolerable
while S419P was predicted marginally tolerable (p = 0.11,
threshold p = 0.05).
Among other noteworthy observations was a tendency of
substitutions to accumulate in families. Substitutions are
introduced into the pedigree of both family F and G and
seem to be highly accumulated in family I. Accumulation
of substitutions is a trait expected to appear in highly con-
sanguineous families when clinical symptoms are known
or anticipated (selection bias).
Gene dosage
Gene dosage analysis was performed with SALSA MLPA
probe set P051 and P052B in affected and/or informative
family members of all families. In members of family F,
an exon 4 deletion was identified to segregate in a reces-
sively inheritance pattern and homozygous deletions
were identified in both affected. Family H had inconsist-
ent control samples and no result was achieved. The
extent of the deletion was investigated and a composite
exon 4 deletion was observed consisting of one large
~25.600 bp and one small ~400 bp deletion (figure 4).
Haplotype segregation
DNA samples were genotyped using four microsatellite
markers located within the parkin gene with the intent to
study the inheritance of markers and assess whether if an
inherited haplotype could explain the development of PD
in some of these families. Homozygous haplotypes were
observed only in the two affected in family F. Figure 3a
shows the pedigree of family F, where the two patients II.2
and II.4 are homozygous for all markers analysed within
the parkin gene. We looked at correct phasing to identify
any recombination events. Recombination was observed
in a healthy individual in family B, offspring II.5 (family
tree not shown) and family F, offspring III.2. We also
observed recombination events in both the affected off-
spring (II.1 and II.2) in family K (family tree not shown).
The haplotype segregation analysis was used to establish
family relations together with results from the AmpFlSTR®
profiler® kit. Based on these results, two families were
excluded prior to this study. A female cousin in family G
was also excluded prior to this study along with two mem-
bers of family F.
Discussion
The families included in our study are from regions with
a high prevalence of consanguinity, favouring an
a-b: Segregation pattern of genetic variation in family F Figure 3
a-b: Segregation pattern of genetic variation in family F. Parents of the two affected are 1st cousins. One affected (II.2) 
is married to his 1st cousin, whereas the other affected (II.4), is married to his 3rd cousin. a Segregation of haplotype and parkin 
exon 4 deletion. Both patients were homozygous for a haplotype of four parkin microsatellite markers, and an exon 4 deletion 
was found to segregate with disease in the family. Gray area denotes haplotype containing exon 4 deletion. b Segregation of 
substitutions observed in PINK1. Both affected are compound heterozygous for the substitutions generally evaluated as com-
mon polymorphisms. One of the children, III.2, had a microsatellite mutation or a rarer double recombination (arrow). The 
fragment lengths of microsatellite markers D6S1599, D6S305, D6S411 and D6S1550 are listed beneath each individual.
b) a)BMC Neurology 2008, 8:47 http://www.biomedcentral.com/1471-2377/8/47
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increased frequency of genetic homozygosity and diseases
with recessive inheritance. From the literature, it is well
known that genetic variation within the parkin gene cause
autosomal recessive juvenile parkinsonism (AR-JP)
[6,10,17-20,22,40] and is the most common cause of
familial parkinsonism known to date [10], while muta-
tions in the PINK1 gene are recognized as an increasingly
important genetic cause of early-onset parkinsonism. A
possible effect of heterozygous mutations in both parkin
and PINK1 have been proposed and a digenic effect have
been observed [47]. To this end we identified an exon 4
deletion in parkin that was homozygous in both affected
(figure 3a) and additional substitutions in PINK1, which
co-segregated with disease (figure 3b). Some substitutions
acknowledged to be common in populations are here dis-
cussed according to possible role in disease development.
In our material we identified four non-synonymous sub-
stitutions in the kinase domain of PINK1, of which two
are novel and proposed to be putative pathogenic muta-
tions. The protein kinase domain in PINK1 that is located
to amino acids 156–509, has a high degree of homology
to similar kinases in the Ca2+/calmodulin family [7].
Functional studies indicate that mutations in the kinase
domain are expected to effect kinase activity as well as
substrate binding capability [33].
Affected individuals in these families were either
homozygous or compound heterozygous and most sub-
stitutions were evaluated to be non-pathogenic polymor-
phisms but could be discussed in relation to impact of a
single hit as well as accumulative effect of substitutions.
The P416R and S419P substitutions are novel and
homozygous in two affected in each of their respective
families (figure 1c, e). Both are in conserved regions of the
gene and predictions using SIFT software for the tolerabil-
ity of substitutions indicates that especially the P416R
substitution is of probable functional importance to the
protein. The A340T, E476K and N521T substitutions are
assumed to be non-pathogenic polymorphisms
[27,31,46] and the D391D synonymous substitution is
assumed to have no effect [27], although the A340T sub-
stitution has been proposed to contribute to risk of devel-
opment of late-onset PD [57]. Interestingly, in family F,
two of these substitutions were found to co-segregate with
disease. In the other families with PINK1 polymorphisms,
a segregation pattern compatible with recessive inherit-
ance could not be excluded, when taken into account the
possibility of reduced penetrance in some offspring due to
low age.
In family F we observed an E476K substitution and an
N521T substitution segregating with disease. Both
affected in family F were compound heterozygous for
Mapping of the parkin exon 4 deletion in family F Figure 4
Mapping of the parkin exon 4 deletion in family F. A composite deletion was identified consisting of one large ~25.600 
bp and one small ~400 bp deletion and presence of fragment 19 confirmed by two additional flanking primers. Gel pictures rep-
resent control (top row) and patient II.4 of family F (bottom row).BMC Neurology 2008, 8:47 http://www.biomedcentral.com/1471-2377/8/47
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these putative polymorphisms in the PINK1  gene. The
E476K substitution is in the protein serine/threonine
kinase domain of the protein, but only to a small degree
conserved across species (figure 2b). The effect of the sub-
stitution on the enzymatic activity of PINK1 is not known
but the substitution is found as the conserved amino acid
in several species [27] and are common in controls as
well. The N521T substitution is located in a conserved
region at the 3' of the protein outside the 156–509 resi-
dues proposed as the serine/threonine kinase region. This
region is conserved across all mammals and has an
unknown function. The N521T substitution identified in
this region is the most prevalent in our material and thus
far one of the most common substitutions found in cases
as well as healthy family members with parkinsonism. In
previous studies the N521T substitution has been com-
mon and recognised merely as a polymorphism [45,58]
and in studies of early-onset PD homozygous incidences
have been confirmed in controls and cases equally
[27,31].
The exon 4 deletion in the parkin gene segregates with dis-
ease and explains the clinical manifestations. It is curios
thou, how additional substitutions are accumulated in the
PINK1 gene as revealed in this study, and for this reason
the observed substitutions will be discussed.
The A340T substitution introduced into the pedigree of
family F was equally found in compound heterozygous
state with N521T in family J. Threonine is the conserved
amino acid in Rattus norwegicus and Mus musculus (figure
2) and this suggests the substitution is most likely a poly-
morphism. However, we cannot completely exclude a
possible effect of the A340T polymorphism in combina-
tion with supplementary mutations within PINK1 or in
other genes affecting parkinsonism.
Parkin is located in the third most common fragile site,
FRA6E, proposed to be involved in several types of cancer,
acting as a tumor suppressor gene together with other
common fragile site genes such as FHIT (FRA3B ; 3p14.2)
and WWOX (FRA16D ;16q23) that are also associated
with exon deletions [43,51]. In some cancer cells there are
a high frequency of loss-of-heterozygosity (LOH)
observed in D6S1599 (parkin intron 2) and D6S305 (par-
kin intron 6) [43] as observed in carriers in healthy family
members of family F in our study. The mechanism of
common fragile sites might indicate some of the mecha-
nism behind the observed parkin deletions and associate
the formation of deletions with a FRA6E site mechanism.
The occurrence of parkin mutations could either be inde-
pendently recurrent de novo mutational events or a geo-
graphical spread through founder effect. In general, exon
rearrangements are found to be caused by independent de
novo mutational events, while point mutations are spread
mainly through founder effect [48,49]. The extent of the
exon 4 deletion in family F was further mapped and was
different from one mapped in a geographically close Turk-
ish family [50].
We found a Gln34Arg substitution previously described in
India where it might be the result of a geographic founder
effect [52,53]. In India, the substitution was observed in
heterozygous state in affected with parkinsonism, but also
in older unaffected family members [52].
This might be a dominant negative mutation which con-
tributes to functional variation in the Parkin protein. A
functional example may be that the protein still interacts
and competes with the wild type protein for the target pro-
tein, but lacks functional properties. Therefore, in hetero-
zygous state, this category of mutation might cause a
range of phenotypes in response to genetic and environ-
mental influence. Variation in penetrance is discussed for
several parkinsonism related mutations. Dominant nega-
tive mutations may be a possible explanation of some of
the observed heterozygous mutations having a variable
"dominant nature". It is different from the loss-of-func-
tion mutations generally observed in the parkin  gene,
where a heterozygous state continues to have a normal
phenotype.
Abbas and colleagues [17] previously detected a mutation
in the same location of exon 2 in two British families, in
which a 202-203delAG caused "loss-of-function" of the
Parkin protein [17]. The Gln34Arg substitution has not
yet been functionally characterized, and its function is
therefore still uncertain. The localization to the ubiquitin-
like domain suggests it may effect binding to proteasome
subunits. The substitution was not observed in the carriers
affected sister (patient II.4), who also developed the dis-
ease, stating that this substitution is not involved in dis-
ease development in both cases. More important, the
affected are both carriers of homozygous P416R substitu-
tions which probably cause the clinical symptoms (see
discussion on P416R further down).
The Val380Leu mutation has, in previous studies, been
found in both healthy and affected individuals. Abbas et
al. [17] reported that the substitution was found in eleven
European families and also 16% of the control subjects
and it appear to be common across populations [52,54]
and therefore not considered a main cause of disease
development. It might, however, alter the Parkin protein
and contribution to the pathogenesis of idiopathic PD, as
noted in a study by Lucking et al. [55], which reported
homozygous Val380Leu substitutions to be associated
with sporadic PD. Biswas et al [56] commented on this
substitution that it might be an association in some pop-
ulations when ethnically stratified. In our study the sub-BMC Neurology 2008, 8:47 http://www.biomedcentral.com/1471-2377/8/47
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stitution was heterozygous in one affected and absent in
the carriers brother who also developed young-onset par-
kinsonism implying that the substitution was not
involved in development of disease in both affected fam-
ily members (figure 1a).
A recessive pattern of inheritance should, in a population
with high degree of consanguinity, anticipate the observa-
tion of homozygous haplotypes identical by decent (IBD)
in the parkin gene, as found in family F where the exon 4
deletion and all four microsatellite markers segregated
with disease. Further haplotype assessment did not reveal
any haplotype that could associate the parkin gene with
the observed symptoms of young-onset or juvenile par-
kinsonism across families. Sequencing revealed few sub-
stitutions and we were unable to identify specific point
mutations in remaining families. Quantitative analysis
revealed no exon rearrangements or complete gene dele-
tions/multiplications that could associate the parkin gene
with the observed clinical symptoms. We confirmed less
than expected incidences of parkin caused parkinsonism
in the population. Multiple sequence alignment and esti-
mation of the tolerability of the observed parkin substitu-
tions indicated that they were probably tolerable (Figure
2a). The reported frequency of parkin associated parkin-
sonism was similarly low in populations of India where
the Gln34Arg substitution was previously observed
[52,53].
In PINK1, the novel P416R substitution was identified in
family G, in a highly conserved motif of the activation seg-
ment in the serine/threonine kinase domain [33]. The
substitution was homozygous in both affected members
of the family and were the centre amino acid of an APE
motif conserved in orthologous sequences and in paralo-
gous protein kinases [33]. Located in a universally con-
served functional motif the substitution is likely to affect
kinase activity.
The S419P substitution was identified in family I. Two
non-synonymous substitutions and one synonymous
substitution, all in homozygous state, were identified in
both affected members of the family (figure 2). Located in
the serine/threonine kinase domain the S419P substitu-
tion was the most conserved alteration within the mate-
rial.
There were no obvious differences between the ages at
onset amongst putative parkin and PINK1 mutation carri-
ers as compared to non-carriers (Table 1). However, there
are similarities regarding age at onset within affected of
the same family. For affected carrying P416R, the only
substitution to be in a universally highly conserved motif,
an earlier age at onset was seen in both affected, as com-
pared to family I carrying three homozygous substitu-
tions, amongst them the S419P substitution. These
findings indicate a severe function of the P416R mutation,
which could represent a total loss-of-function mutation.
Otherwise, the observed variations in age at onset could
generally be due to interactions of additional environ-
mental or genetic factors such as accumulation of substi-
tutions causing gradual alterations in protein structure. In
light of the SIFT predictions, assessment of the tolerability
of the S419P substitution is dependent on further func-
tional analysis.
In some families an accumulation of substitutions are
observed. In family F both deletion in parkin and substitu-
tions in PINK1 co-segregate with disease, and a carrier of
A340T and N521T is married in. In family G a carrier of
N521T is married in to the family through a healthy fam-
ily member. In family I, the accumulation of substitutions
in the two affected, the only two persons available for
analysis, are notable. The possibility of a LOH for this
region was excluded using the gene and exon dosage
SALSA MLPA kit. Accumulation of substitutions should
suggest some selective bias based on knowledge of disease
in families and therefore suggest a role of these substitu-
tions in disease or in association to disease.
Conclusion
The role of digenic inheritance of parkin  and  PINK1,
impact of a single mutation hit and accumulation load of
gene polymorphisms are unclear. We observed a three
generation family with an exon 4 deletion in the parkin
gene and substitutions in the PINK1 gene co-segregating
with disease indicating a potential digenic effect.
We identified two novel substitutions in the PINK1 ser-
ine/threonine kinase domain with the P416R as probable
and the S419P as possible putative pathogenic mutation
and the genetic cause of young-onset parkinsonism in two
families.
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